Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Molecular Prognostic Markers in Recurrent and in Non-recurrent Epithelial Ovarian Cancer

ATTILA DEMETER, ISTVAN SZILLER, ZSOLT CSAPO, JULIANNA OLAH, GERGELY KESZLER, ANDRAS JENEY, ZOLTAN PAPP and MARIA STAUB
Anticancer Research July 2005, 25 (4) 2885-2889;
ATTILA DEMETER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ISTVAN SZILLER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ZSOLT CSAPO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JULIANNA OLAH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GERGELY KESZLER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDRAS JENEY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ZOLTAN PAPP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIA STAUB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: staub@puskin.sote.hu
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The outcome and prognosis of ovarian cancer is highly variable. The objective of this study was to compare survival and clinicopathological prognostic factors with the expression levels of two matrix metalloproteinases (MMP) and fibronectin as tumor invasion and metastasis markers in ovarian cancer patients. Materials and Methods: Histologically-verified epithelial ovarian tumours from 27 patients were studied. The latent and the activated forms of MMP-2 and MMP-9 were measured as gelatinase activity from tumour extracts and from serum and ascites samples by a zymographic technique. The fibronectin content was quantified by immunoblotting and densitometric analysis. Molecular marker levels were correlated to clinicopathological parameters such as survival and disease recurrence during the median postoperative follow-up period of 30 months. Results: The levels of MMP-9 and fibronectin, but not those of MMP-2, were significantly higher in tumour tissues and in the ascites fluid of the recurrent patient group and the patient group who did not survive, as compared to the non-reccurent cases. Conclusion: Our data support that high expression of MMP-9 and fibronectin indicate poor prognosis for ovarian cancer patients who have similar clinicopathological prognostic factors.

  • Ovarian cancer
  • invasion markers
  • matrix metallo-proteinase
  • fibronectin
  • prognosis

Footnotes

  • Received February 16, 2005.
  • Accepted May 30, 2005.
  • Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (4)
Anticancer Research
Vol. 25, Issue 4
1 Jul 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Molecular Prognostic Markers in Recurrent and in Non-recurrent Epithelial Ovarian Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
17 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Molecular Prognostic Markers in Recurrent and in Non-recurrent Epithelial Ovarian Cancer
ATTILA DEMETER, ISTVAN SZILLER, ZSOLT CSAPO, JULIANNA OLAH, GERGELY KESZLER, ANDRAS JENEY, ZOLTAN PAPP, MARIA STAUB
Anticancer Research Jul 2005, 25 (4) 2885-2889;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Molecular Prognostic Markers in Recurrent and in Non-recurrent Epithelial Ovarian Cancer
ATTILA DEMETER, ISTVAN SZILLER, ZSOLT CSAPO, JULIANNA OLAH, GERGELY KESZLER, ANDRAS JENEY, ZOLTAN PAPP, MARIA STAUB
Anticancer Research Jul 2005, 25 (4) 2885-2889;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • MMP-2 mRNA Expression in Ovarian Cancer Tissues Predicts Patients' Response to Platinum-Taxane Chemotherapy
  • WOMEN IN CANCER THEMATIC REVIEW: Ovarian cancer-peritoneal cell interactions promote extracellular matrix processing
  • Synergistic Enhancement of Carboplatin Efficacy with Photodynamic Therapy in a Three-Dimensional Model for Micrometastatic Ovarian Cancer
  • Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers
  • Matrix Metalloproteinase 9 Is a Mediator of Epidermal Growth Factor-Dependent E-Cadherin Loss in Ovarian Carcinoma Cells
  • Engagement of Collagen-Binding Integrins Promotes Matrix Metalloproteinase-9-Dependent E-Cadherin Ectodomain Shedding in Ovarian Carcinoma Cells
  • Google Scholar

More in this TOC Section

  • Docosahexaenoic Acid Potentiates the Anticancer Effect of the Menadione/Ascorbate Redox Couple by Increasing Mitochondrial Superoxide and Accelerating ATP Depletion
  • Streptonigrin Mitigates Lung Cancer-induced Cachexia by Suppressing TCF4/TWIST1-induced PTHLH Expression
  • Atezolizumab Retains Cellular Binding to Programmed Death Ligand 1 Following Aerosolization via Mesh Nebulizer
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire